Company Overview - Relay Therapeutics has been established for nearly 10 years, focusing on precision medicine targets [2] - The company has navigated a challenging environment for biotechs over the past few years [2] Strategic Focus - Relay Therapeutics has out-licensed its lead program, an FGFR2 inhibitor, to adapt to market conditions [2] - The company has streamlined its research organization and staggered some preclinical programs [3] Key Research Initiatives - The primary focus is now on the PI3K-alpha inhibitor, zovegalisib, which is believed to be the first mutant selective inhibitor entering clinical trials [3] - There are three major opportunities identified for zovegalisib: hormone receptor positive, HER2-negative frontline and second-line metastatic breast cancer, and PI3K-alpha-driven vascular amalgamations [3]

Core Viewpoint - Cogent Biosciences, Inc. has announced a public offering of 22,222,223 shares of common stock at a price of $9.00 per share, aiming to raise approximately $200 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 3,333,333 shares on the same terms [1]. - The expected closing date for the offering is around July 10, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the development, regulatory, and commercial preparation activities related to bezuclastinib and other product candidates [2]. - Funds will also support the planned commercial launch of bezuclastinib, along with working capital and general corporate purposes [2]. Group 3: Company Overview - Cogent Biosciences focuses on developing precision therapies for genetically defined diseases, with bezuclastinib being the most advanced clinical program [5]. - Bezuclastinib is a selective tyrosine kinase inhibitor targeting the KIT D816V mutation, which is associated with systemic mastocytosis and advanced gastrointestinal stromal tumors [5]. - The company is also conducting a Phase 1 study of a novel FGFR2 inhibitor and developing therapies targeting mutations in ErbB2, PI3Kα, and KRAS [5].